Phase I study of azacitidine [Vidaza] in combination with cisplatin patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Trial Profile

Phase I study of azacitidine [Vidaza] in combination with cisplatin patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Azacitidine (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Aug 2009 Celgene Corporation added as trial sponsor and lead trial centre as reported by ClinicalTrials.gov.
    • 12 Jun 2008 Patient numbers amended from 24 to 1 as reported by ClinicalTrials.gov
    • 12 Jun 2008 Status changed from recruting to discontinued as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top